Haemodynamic effects of 8-day octreotide and prazosin administration in portal hypertensive rats.
BACKGROUND
Octreotide and prazosin are both effective portal hypotensive drugs in the control or prevention of variceal bleeding. The present study was undertaken to investigate the haemodynamic effects of octreotide and prazosin, alone or in combination, in portal hypertensive rats.


METHODS
Portal hypertension was induced by partial portal vein ligation. Portal hypertensive rats were allocated into one of the four groups-vehicle group (saline, 0.5 mL 12 h-1), octreotide group (30 micrograms kg-1 12 h-1), prazosin group (0.4 mg kg-1 12 h-1), and octreotide (30 micrograms kg-1 12 h-1) plus prazosin (0.4 mg kg-1 12 h-1) group-with eight rats in each group. Prazosin or saline was administered by gavage, whereas octreotide was administered by subcutaneous injection. The drug was given on the day of ligation and continued for 8 consecutive days. Systemic as well as splanchnic haemodynamic parameters were measured thereafter.


RESULTS
Portal vein-ligated rats exhibited typical hyperdynamic state compared with sham-operated rats. The portal venous pressure, portal tributary blood flow and cardiac index were significantly reduced by treatment of octreotide, prazosin or octreotide plus prazosin in portal hypertensive rats. Hyperdynamic parameters of systemic, renal and portal territory vascular resistances, and renal as well as hepatic arterial blood flow were ameliorated by treatment of octreotide or octreotide plus prazosin in portal hypertensive rats. Overall, octreotide treatment exerted more beneficial haemodynamic effects than prazosin treatment. The combination of octreotide and prazosin exerted better haemodynamic effects in cardiac index but worse effects in systemic as well as portal territory vascular resistance than octreotide treatment alone.
Lin
H C
HC
Veterans General Hospital, Taipei, Taiwan.
Wu
H L
HL
Huang
Y T
YT
Hou
M C
MC
Lee
S D
SD
Hong
C Y
CY
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D006499:Hepatic Artery / Q000502:physiology; D006975:Hypertension, Portal / Q000188:drug therapy*; D008026:Ligation; D008102:Liver Circulation / Q000187:drug effects; D008863:Microspheres; D015282:Octreotide / Q000494:pharmacology*; D011169:Portal Vein; D011224:Prazosin / Q000494:pharmacology*; D051381:Rats; D014655:Vascular Resistance; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D000959:Antihypertensive Agents; D014662:Vasoconstrictor Agents; D015282:Octreotide; D011224:Prazosin